Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 34.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,261 shares of the specialty pharmaceutical company’s stock after selling 108,118 shares during the period. Los Angeles Capital Management LLC owned about 0.32% of Jazz Pharmaceuticals worth $24,236,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Baupost Group LLC MA raised its position in shares of Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares in the last quarter. Polaris Capital Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 4th quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after acquiring an additional 27,100 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $380,000. International Assets Investment Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $7,201,000. Finally, Desjardins Global Asset Management Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $1,943,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ JAZZ traded down $1.85 during mid-day trading on Wednesday, hitting $112.68. 604,542 shares of the company traded hands, compared to its average volume of 939,034. Jazz Pharmaceuticals plc has a 1 year low of $103.01 and a 1 year high of $146.70. The stock has a market capitalization of $7.11 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.76 and a beta of 0.62. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The business has a 50 day moving average of $109.28 and a two-hundred day moving average of $117.42.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The company had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on JAZZ. Truist Financial reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 31st. Piper Sandler upped their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $190.92.

View Our Latest Stock Analysis on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.